WebFULL PRESCRIBING INFORMATION REBLOZYL ® (luspatercept-aamt) 1 INDICATIONS AND USAGE 1.1 Beta Thalassemia REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. 1.2 Myelodysplastic Syndromes with Ring Sideroblasts or Myelodysplastic/ WebNov 15, 2024 · Introduction: Luspatercept, TGF-B fusion trap protein, is a first in class erythroid maturating agent approved by FDA for treatment of red blood cell transfusion dependent (RBC-TD) lower risk myelodysplastic syndromes (LR-MDS) with ring sideroblasts (RS) based on the MEDALIST clinical trial. Red blood cell transfusion independence …
J0896 Injection, luspatercept-aamt, 0.25 mg Healthcare …
WebMay 10, 2024 · Luspatercept exhibited linear pharmacokinetics and first-order absorption and elimination following subcutaneous (SC) injection in healthy volunteers and patients with MDS or β-thalassaemia over a dose range of 0.125–1.75 mg/kg [10, 11, 15].Increasing the dose resulted in approximately proportional increases in the maximum drug … Webluspatercept-aamt to pregnant rats and rabbits during organogenesis resulted in adverse developmental outcomes including increased embryo-fetal mortality, … text trend
Effective Date: 10/06/2024 - BCBSM
Web13 rows · HCPCS Code. J0896. Injection, luspatercept-aamt, 0.25 mg. Drugs administered other than oral ... WebDec 3, 2024 · Reblozyl® (luspatercept-aamt) (Subcutaneous) Document Number: IC-0503 Last Review Date: 12/03/2024 Date of Origin: 12/03/2024 Dates Reviewed: 12/2024 ... B. Max Units (per dose and over time) [HCPCS Unit]: • 150 mg every 21 days III. Initial Approval Criteria1,2,3,4 Coverage is provided in the following conditions: WebJun 6, 2024 · HCPCS code C9399, Unclassified drug or biological, should be used for new drugs and biologicals that are approved by the United States (U.S.) Food and Drug Administration (FDA) on or after January 1, 2004, for which a specific HCPCS code has not been assigned. ... Inj luspatercept-aamt 0.25mg J0897 Denosumab injection J1442 Inj … text trimming